

Pediatric Intestine Transplant Recipient Registration Worksheet

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI^B. application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI^B. application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
St.	
State of Permanent Residence: *	
Permanent Zip: *	-
Provider Information	
Recipient Center:	
Surgeon Name: *	
NPI: *	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Patient Status	
Primary Diagnosis: *	
Specify:	
Secondary Diagnosis:	
Specify:	
Specify.	
Date: Last Seen, Retransplanted or Death ★	
,	
	C LIVING
Patient Status: *	© DEAD
	FETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Dogsh	
Contributory Cause of Death:	
Specify:	

Contributory Cause of Death:	
Specify:	
Transplant Hospitalization:	
Date of Admission to Tx Center: *	
Date of Discharge from Tx Center:	
Was patient hospitalized during the last 90 days prior to the transplant admission:	G YES G NO G UNK
	IN INTENSIVE CARE UNIT
Medical Condition at time of transplant: ★	HOSPITALIZED NOT IN ICU
	NOT HOSPITALIZED
Patient on Life Support: *	C YES NO
	Ventilator
	Artificial Liver
	Other Mechanism, Specify
Specify:	
Functional Status: *	
Functional Status: *	© Definite Cognitive delay/impairment (verified by IQ score <70 or unambiguous behavioral observation)
Functional Status: *	
Functional Status: * Cognitive Development: *	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but
	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as
	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive
	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment)
	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment) Not Assessed Definite Motor delay/impairment (verified by physical exam or unambiguous
	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment) Not Assessed Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation) Probable Motor delay/impairment (not verified or unambiguous but more
Cognitive Development: *	unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment) Not Assessed Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation) Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Motor delay/impairment (not judged to be more likely than

	Within One Grad	le Level of Peers		
	O Delayed Grade L	evel		
Academic Progress: *	Special Education	Special Education		
	Not Applicable <	: 5 years old		
	Status Unknown			
	Full academic lo	ad		
	Reduced acaden	nic load		
Academic Activity Level: *	C Unable to partici	pate in academics due to disease or condition		
	Not Applicable <	5 years old/ High School graduate		
	C Status Unknown			
Source of Payment:				
Primary: *				
Specify:				
Secondary:				
Clinical Information : PRETRANSPLA	NT			
Date of Measurement: *				
Height: *	ft. in.	cm %ile ST=		
Weight: ★	Ibs	kg %ile ST=		
BMI:	kg/m ²	%ile		
Previous Transplants:				
Previous Transplant Organ	Previous Transplant Date	Previous Transplant Graft Fail Date		
The three most recent transplants are listed 978-4334 or by emailing unethelpdesk@un	here. Please contact the UNet Help Deskos.org.	k to confirm more than three previous transplants by calling 800-		
Viral Detection:				
	C Positive			
	Negative			
HIV Serostatus: *	Not Done			
	UNK/Cannot Dis	close		
	C Positive			
010/1 0 4	○ Negative			
CMV IgG: ★	© Not Done			
	- Not Dollo			

	UNK/Cannot Disclose		
	C Positive		
CMV IgM: ★	Negative		
	Not Done		
	UNK/Cannot Disclose		
	© Positive		
LIDVO A CL. L. W	Negative		
HBV Core Antibody: ★	Not Done		
	UNK/Cannot Disclose		
	Positive		
HBV Surface Antigen: ★	Negative		
nov Sunace Anagen. A	Not Done		
	C UNK/Cannot Disclose		
	© Positive		
HCV Serostatus: ★	Negative		
Tiov ociostatus.	Not Done		
	C UNK/Cannot Disclose		
	C Positive		
EBV Serostatus: *	Negative		
EDV Selusialus. 4	Not Done		
	C UNK/Cannot Disclose		
Total Bilirubin: *	mg/dl ST=		
Serum Albumin: *	g/dl ST=		
Serum Creatinine: *	mg/dl ST=		
Malignancies between listing and transplant: *	© YES © NO © UNK		
This question is NOT applicable for patients receiving living of	lonor transplants who were never on the waiting list.		
	Skin Melanoma		
	Skin Non-Melanoma		
	CNS Tumor		
	☐ Genitourinary		

	☐ Breast
	☐ Thyroid
	☐ Tongue/Throat/Larynx
	Lung
If yes, specify type:	Leukemia/Lymphoma
	Hepatoblastoma
	Hepatocellular Carcinoma
	Liver
	Other, specify
Specify:	
ореспу.	
Clinical Information : TRANSPLANT PROCEDURE	
Multiple Organ Recipient	
Were extra vessels used in the transplant procedure:	
Vessel Donor ID:	
Procedure Information:	
Intestine Only Venous Drainage: *	Portal Systemic
Native Viscera Venous Drainage: *	Portal Systemic
	Whole Intestine
Procedure Type:	Intestine Segment
	Whole Intestine with Pancreas (Technical Reasons)
	Intestine Segment with Pancreas (Technical Reasons)
Organ Type: *	☐ Stomach
organi rypor	☐ Small Intestine
	Duodenum
	☐ Large Intestine
	Large intestine
Preservation Information:	
Total Ischemic Time (include cold, warm and anastomotic time): *	hrs ST=
,	
Risk Factors:	
Recent Septicemia: *	C YES O NO O UNK
Exhausted Vascular Access: *	O YES O NO O UNK
Exnausted vascular Access: 1	YES NO UNK

Liver Dysfunction:	G YES G NO G UNK
Previous Abdominal Surgery: *	C YES C NO C UNK
Number Previous Abdominal Surgeries:	ST=
Dilated/Non-Functional Bowel Segments: *	C YES C NO C UNK
Other:	
Clinical Information : POST TRANSPLANT	
Graft Status: *	Functioning Failed
If death is indicated for the recipient, and the death was a re-	sult of some other factor unrelated to graft failure, select Functioning.
TPN Dependent:	C YES C NO
IV Dependent:	C YES C NO
Oral Feeding:	C YES C NO
Tube Feed:	C YES C NO
Date of Graft Failure:	
	C RECURRENT TUMOR
	C ACUTE REJECTION
	CHRONIC REJECTION
	C TECHNICAL PROBLEMS
Primary Cause of Graft Failure:	INFECTION
	C LYMPHOPROLIFERATIVE DISEASE
	GVHD (Graft Versus Host Disease)
	☐ ISCHEMIA/NEC (Necrotizing Enterocolitis) LIKE SYNDROME
	OTHER SPECIFY
Specify:	
Did nations have any courte rejection enjoyees	Yes, at least one episode treated with anti-rejection agent
Did patient have any acute rejection episodes between transplant and discharge: *	Yes, none treated with additional anti-rejection agent
	○ No
	Biopsy not done
Was biopsy done to confirm acute rejection:	Yes, rejection confirmed
	Yes, rejection not confirmed

Treatment	
Biological or Anti-viral Therapy:	C YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
	☐ Gammagard
	Ganciclovir (Cytovene)
If Yes, check all that apply:	☐ Valgancyclovir (Valcyte)
	HBIG (Hepatitis B Immune Globulin)
	Flu Vaccine (Influenza Virus)
	Lamivudine (Epivir) (for treatment of Hepatitis B)
	Other, Specify
	☐ Valacyclovir (Valtrex)
Specify:	
Specify:	
Other therapies:	© YES © NO
	Photopheresis
If Yes, check all that apply:	Plasmapheresis
	Total Lymphoid Irradiation (TLI)
Immunosuppressive Information	
Are any medications given currently for maintenance or anti-rejection: ★	C YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	© YES © NO
If Yes, Specify:	
Immunequippressive Medications	
Immunosuppressive Medications View Immunosuppressive Medications	
Definitions Of Immunosuppressive Medications	
	ct Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications ant hospitalization period, and for what reason. If a medication was not given, leave the
acute rejection. Though the drugs may be continued after dis immunosuppressive maintenance. Induction agents are usua Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some	s given for a short finite period in the perioperative period for the purpose of preventing scharge for the first 30 days after transplant, it will not be used long-term for ally polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, of these drugs might be used for another finite period for rejection therapy and would be h induction medication indicated, write the total number of days the drug was actually

<u>administered</u> in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart, then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

	Ind.	Days	ST
Steroids Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)			
utgam (ATG)			
OKT3 (Orthoclone, Muromonab)			
hymoglobulin			
Simulect - Basiliximab			
enapax - Daclizumab			
zathioprine (AZA, Imuran)			
ON (Generic Cyclosporine)			
engraf (Abbott Cyclosporine)			
ther generic Cyclosporine, specify brand:			
eoral (CyA-NOF)			
andimmune (Cyclosporine A)			
ycophenolate Mofetil (MMF, Cellcept, RS61443)			
acrolimus (Prograf, FK506)			
lodified Release Tacrolimus FK506E (MR4)			
irolimus (RAPA, Rapamycin, Rapamune)			

Myfortic (Mycophenolate Sodium)			
Other Immunosuppressive Medications			
	Ind. Days	ST	Maint AR
Campath - Alemtuzumab (anti-CD52)			
Cyclophosphamide (Cytoxan)			
Leflunomide (LFL, Arava)			
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)			
Other Immunosuppressive Medication, Specify			
Other Immunosuppressive Medication, Specify			
Rituximab			
Investigational Immunosuppressive Medications			
	Ind. Days	ST	Maint AR
Everolimus (RAD, Certican)			
FTY 720			
Other, Specify			
UNOS View Only			
Comments:			